ClinicalTrials.gg
CompletedNCT02689063Updated Jul 6, 2021Results posted

Maxigesic IV Phase 3 Bunionectomy Study

A Phase 3 interventional study of Maxigesic IV and IV Acetaminophen in Post Operative Pain, sponsored by AFT Pharmaceuticals, Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-06.

Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.

Enrollment
14th of 118
276 · median 90
Started
2016
with 5 others
Phase 3
20 of 118
1 open now
Registered
47th of 118
by date

Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 14th largest by enrollment, is one of 6 that started in 2016, is one of 20 in phase 3, and was the 47th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies testing acetaminophen in Pain, Postoperative, or all of them as a file.
02

Study summary

The purpose of the study is to determine the clinical efficacy and safety of Maxigesic IV, acetaminophen IV, Ibuprofen IV versus placebo IV for the treatment of acute postoperative pain after bunionectomy

Read the detailed description

AFT Pharmaceuticals Ltd. has been developing a fixed-dose combination of acetaminophen 1000mg and ibuprofen 300mg/100mL solution for infusion (Maxigesic IV) for the temporary relief of postoperative pain, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration not possible.

A phase 3 efficacy study (AFT-MXIV-07) is proposed to determine the analgesic effects of the fixed dose combination product Maxigesic IV versus its individual components (acetaminophen IV and ibuprofen IV) and placebo in participants with acute post-operative pain after bunionectomy.

The primary efficacy objective is to determine the efficacy of Maxigesic IV, acetaminophen IV, Ibuprofen IV versus placebo IV as measured by the summed pain intensity difference (SPID) (calculated as a time-weighted average) over 0-48 hours (SPID-48) after time 0.

Other secondary efficacy endpoints are:

VAS Pain intensity difference (PID) at each scheduled assessment time point after Time 0 VAS Pain intensity score at each scheduled assessment time point VAS SPID over 0 to 6 hours (SPID-6), over 0 to 12 hours (SPID-12), and over 0 to 24 hours (SPID-24) after Time 0

Summed pain relief (TOTPAR) (calculated as a time-weighted average) over 0 to 6 hours (TOTPAR-6), over 0 to 12 hours (TOTPAR-12), over 0 to 24 hours (TOTPAR-24) after Time 0, and over 0 to 48 hours (TOTPAR-48) after Time 0

Time to onset of analgesia (measured as time to perceptible pain relief confirmed by meaningful pain relief) using the two-stopwatch method Pain relief score on a 5-point categorical scale at each scheduled time point after Time 0

Peak pain relief

Time to peak pain relief

Time to first perceptible pain relief

Time to meaningful pain relief

Proportion of subjects using rescue medication

Time to first use of rescue medication (duration of analgesia)

Total use of rescue analgesia over 0 to 24 hours and over 0 to 48 hours Patient's global evaluation of study drug

03

Conditions studied

  • Post Operative Pain

Browse trials for

Keywords

  • Analgesic
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female ≥ 18 and ≤ 65 years of age.
  2. Is classified by the anesthesiologist as P1 to P2 in the (ASA) Physical Status Classification System.
  3. Has undergone primary, unilateral, distal, first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.
  4. Experiences a pain intensity rating of ≥ 40 mm on a 100-mm Visual Analogue Scale (VAS) during the 9-hour period after discontinuation of the anesthetic block.
  5. Has a body weight ≥ 45 kg and a (BMI) ≤ 40 kg/m2.
  6. If female and of , is nonlactating and nonpregnant (has negative pregnancy test results at Screening [urine] and on the day of surgery prior to surgery [urine]).
  7. If female, is either not of childbearing potential (defined as for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy, or hysterectomy]) or practicing 1 of the following medically acceptable methods of :

    Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject's usual menstrual cycle period) before study drug administration.

    Total abstinence from sexual intercourse since the last menses before study drug administration through completion of final study visit.

    Intrauterine device (IUD). Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream).

  8. Is able to provide written to participate in the study and able to understand the procedures and study requirements.
  9. Must voluntarily sign and date an informed consent form (ICF) that is approved by an Institutional Review Board (IRB) before the conduct of any study procedure.
  10. Is willing and able to comply with study requirements (including diet, alcohol, and smoking restrictions), complete the pain evaluations, remain at the study site for approximately 72 hours, and return for follow-up 7 ± 2 days after surgery.

Exclusion criteria

Exclusion Criteria:

  1. Has a known history of allergic reaction or intolerance to acetaminophen, aspirin, opioids, or any nonsteroidal anti-inflammatory drugs (NSAIDs, including ibuprofen); history of NSAID-induced bronchospasm (subjects with the triad of asthma, nasal polyps, and chronic rhinitis are at greater risk for bronchospasm and should be considered carefully); or , allergy, or significant reaction to sulfa (including sulfonamide) medicines, ingredients of the study drug, or any other drugs used in the study including anesthetics and antibiotics that may be required on the day of surgery.
  2. Has experienced any surgical complications or other issues that, in the opinion of the investigator, could compromise the safety of the subject if he or she continues into randomized treatment period or could confound the results of the study.
  3. Has known or suspected history of alcoholism or drug abuse or misuse within 2 years of screening or evidence of tolerance or physical dependence before dosing with study drug.
  4. Has any clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease or any other condition that, in the opinion of the investigator, could compromise the subject's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.
  5. Has any ongoing condition, other than a condition associated with the current primary, unilateral, first metatarsal bunionectomy that could generate levels of pain sufficient to confound the results of the study (eg, gout, severe osteoarthritis of the target joint or extremity).
  6. Has a history or current diagnosis of a significant psychiatric disorder that, in the opinion of the investigator, would affect the subject's ability to comply with the study requirements.
  7. Has tested positive either on the urine drug screen or on the alcohol breathalyzer test. Subjects who test positive at Screening only and can produce a prescription for the medication from their physician may be considered for study enrolment at the discretion of the investigator.
  8. Has a history of a clinically significant (investigator opinion) gastrointestinal (GI) event within 6 months before Screening or has any history of peptic or gastric ulcers or GI bleeding.
  9. Has a surgical or medical condition of the GI or renal system that might significantly alter the absorption, distribution, or excretion of any drug substance.
  10. Is considered by the investigator, for any reason (including, but not limited to, the risks described as precautions, warnings, and in the current version of the Investigator's Brochure for IV Maxigesic®), to be an unsuitable candidate to receive the study drug.
  11. Is receiving systemic chemotherapy, has an active of any type, or has been diagnosed with cancer within 5 years before Screening (excluding treated squamous or basal cell carcinoma of the skin).
  12. Is currently receiving anticoagulants (eg, heparin or warfarin).
  13. Has received a course of systemic (either oral or parenteral) within 3 months before Screening (inhaled nasal steroids and regional/limited area application of topical corticosteroids (investigator discretion) are allowed).
  14. Has received or will require any analgesic medication within 5 half-lives (or, if half-life is unknown, within 48 hours) before surgery.
  15. Has a history of chronic use (defined as daily use for > 2 weeks) of NSAIDs, opiates, or glucocorticoids (except inhaled nasal steroids and regional/limited topical corticosteroids), for any condition within 6 months before study drug administration. Aspirin at a daily dose of ≤ 325 mg is allowed for cardiovascular prophylaxis if the subject has been on a stable dose regimen for ≥ 30 days before Screening and has not experienced any relevant medical problem.
  16. Has been treated with agents that could affect the analgesic response (such as central alpha agents [clonidine and tizanidine], neuroleptic agents, and other antipsychotic agents) within 2 weeks before dosing with study drug.
  17. Has a significant renal or hepatic disease, as indicated by clinical laboratory assessment (results ≥ 3 times the [ULN] for any liver function test, including [AST], alanine aminotransferase [ALT], and lactate dehydrogenase, or creatinine ≥ 1.5 times the ULN).
  18. Has any clinically significant laboratory finding at Screening that, in the opinion of the investigator, contraindicates study participation.
  19. Has significant difficulties swallowing capsules or is unable to tolerate oral medication.
  20. Previously participated in another clinical study of Maxigesic® IV or received any drug or device or investigational therapy within 30 days before Screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
276 participants (actual)

Study arms

  • Experimental
    Maxigesic IV

    intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours

    Drug: Maxigesic IV

  • Active comparator
    IV Acetaminophen

    IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours

    Drug: IV Acetaminophen

  • Active comparator
    IV Ibuprofen

    IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours

    Drug: IV Ibuprofen

  • Placebo comparator
    Placebo IV

    Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours

    Drug: Placebo IV

Interventions

  • DrugMaxigesic IV

    Drug pages: Acetaminophen · Ibuprofen

    IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours

    Also known as: Maxigesic

  • IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours

    Also known as: Acetaminophen

  • IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours

    Also known as: Ibuprofen

  • DrugPlacebo IV

    Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Summed Pain Intensity Difference (SPID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).

    A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced. The extent of pain relief can then be calculated by the Area Under the Curve the PID scores (also referred to as the Sum of Pain Intensity Differences \[SPID\]). SPID48 scores were adjusted by the time interval from baseline to the final VAS score used in the SPID, using the following formula: Time-adjusted SPID48 (mm) = SPID (mm\*hr) / Time (hr) In the event that a patient required rescue medication, the SPID was calculated up until the first Pre-Rescue VAS pain assessment (inclusive).

    Time frame: 48 hours after the first dose

Secondary outcomes

  1. VAS Pain Intensity Difference (PID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).

    VAS Pain intensity difference (PID) at each scheduled assessment time point after Time 0. A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced.

    Time frame: 48 hours after the first dose

  2. VAS Pain Intensity Score-marking on a 100 mm VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). A High VAS Score Indicates a More Intensive Pain Level Experienced.

    VAS Pain intensity score at each scheduled assessment time point VAS pain intensity score-marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). A high VAS score indicates a more intensive pain level experienced.

    Time frame: 48 hours after the first dose

  3. SPID-6, SPID-12, SPID-24-VAS SPID Over 0 to 6 Hours (SPID-6), Over 0 to 12 Hours (SPID-12), and Over 0 to 24 Hours (SPID-24) After Time 0 (=the First Dose)

    Time adjusted SPID-6, SPID-12, SPID-24 were derived in a similar manner to the Time-adjusted SPID-48 (i.e. up until the first Pre-Rescue VAS inclusive). Please see the primary outcome measure descriptions. Each of these variables were derived from VAS (Visual Analogue Scale) scores recorded prior to the first dose of rescue medication in the first 6 (to calculate SPID6), 12 (to calculate SPID12) or 24 hours (to calculate SPID24) of the study. VAS pain intensity scores were obtained by marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). The VAS was completed at rest.

    Time frame: 6, 12, 24 hours after the first dose

  4. TOTPAR-6, TOTPAR-12, TOTPAR-24, TOTPAR-48

    Total Pain Relief (TOTPAR) is a measure of total Area Under the Curve of Pain Relief scores. In the event that a patient required rescue medication, the TOTPAR endpoints were calculated using Pain Relief Assessments recorded prior to the first dose of rescue (i.e. inclusive of the first pre-rescue Pain Relief score). Pain relief scores were obtained by marking on a 5-point categorical rating at scheduled time points. The high score means more pain relief experienced: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Each of these variables were derived from pain relief scores recorded prior to the first dose of rescue medication in the first 6 (0-48), 12 (0-48), 24 (0-48) or 48 (0-48) hours of the study.

    Time frame: 6, 12, 24, 48 hours after the first dose

  5. Time to the Onset of Analgesia-Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Meaningful Pain Relief) Using the Two-stopwatch Method

    Two-stopwatch method 1. Start two stopwatches ('Stopwatch A' and 'Stopwatch B') at the same time that the infusion of study drug is initiated. This is Time 0. 2. The participant is given 'Stopwatch A' and instructed to "Stop 'Stopwatch A' when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now." (Perceptible Pain Relief) 3. When the participant stops the 'Stopwatch A', the participant then was asked "Do you consider the pain relief you experienced meaningful?" 4. If the participant answered "No", then the participant was given the "Stopwatch B" and instructed to "Stop 'Stopwatch B' when you feel the pain relief is meaningful to you" (Meaningful Pain Relief) 5. If the subject did not experience "perceptible pain relief, they would retain 'Stopwatch A' for the entire 6 hour evaluation period.

    Time frame: 6 hours

  6. Percentage of Participants With Complete Pain Relief

    Pain relief score was assessed on a 5-point categorical scale at each scheduled time point after Time 0: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Assessed at scheduled time points: * 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6 hours after the first dose of the study drug * Immediately before and 2 hours after each subsequent dose (doses 2-8) of the study drug while awake * At the end of 48 hours of double-blind treatment period * Immediately before taking each dose of the rescue medication if additional analgesia is required. * At the time of withdrawal (if applicable)

    Time frame: 48 hours after the first dose

  7. Percentage of Participants Who Obtained a Peak Pain Relief -Value of 3 ('A Lot of Relief') or 4 ('Complete Relief') Prior to the First Dose of Rescue

    Peak Pain Relief was assessed on Pain Relief scores (on a 5 point categorical rating-please see outcome measure description No. 7) recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). The percentage of participants who achieve the peak pain relief was summarized.

    Time frame: 48 hours after the first dose

  8. Time to Peak Pain Relief

    Time to peak pain relief-Peak Pain Relief was assessed on Pain Relief scores recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). Time for participants who experienced peak pain relief was summarized. Note: For the reader to interpret this outcome measure, a very short Time to Peak Pain Relief indicates the absence of analgesic effect for a treatment because peak pain relief was determined prior to the first dose of rescue medication (or 48 hours if no rescue medication was used).

    Time frame: 48 hrs after the first dose

  9. Percentage of Subjects Using Rescue Medication

    The percentage of participants who used at lease one dose of rescue medication was summarized in each treatment group

    Time frame: 48 hrs after the first dose

  10. Time to the First Dose of Rescue Medication

    Time to first use of rescue medication (duration of analgesia)

    Time frame: 48 hrs

  11. Total Use of Rescue Medication

    Total use of rescue analgesia over 0 to 24 hours and over 0 to 48 hours

    Time frame: 24, 48 hrs after the first dose

  12. The Percentage of Participants Who Evaluated Their Study Drug as " Excellent" on a 5-point Categorical Scale Global Evaluation of Study Drug

    At the end of 48 hours study period, participants will be asked to " How do you rate the study medication?" on a 5 point categorical scale: 1. Poor 2. Fair 3. Good 4. Very Good 5. Excellent The high score means the participants believed that a better treatment for pain relief received.

    Time frame: 48 hrs after the first dose

  13. Number of Participants With Treatment Emergent Adverse Events (AEs)

    Treatment-emergent Adverse events coded to MedDRA v 20.0 Preferred Term and System Organ Class Code were tabulated as the counts and percentages by treatment group.

    Time frame: Day 7

07

Results

Posted Jul 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Started75757650
Completed75737350
Not completed0230

Outcome measures

PrimarySummed Pain Intensity Difference (SPID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).

A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced. The extent of pain relief can then be calculated by the Area Under the Curve the PID scores (also referred to as the Sum of Pain Intensity Differences \[SPID\]). SPID48 scores were adjusted by the time interval from baseline to the final VAS score used in the SPID, using the following formula: Time-adjusted SPID48 (mm) = SPID (mm\*hr) / Time (hr) In the event that a patient required rescue medication, the SPID was calculated up until the first Pre-Rescue VAS pain assessment (inclusive).

Time frame:
48 hours after the first dose
Reported as:
Mean · score on a scale
Summed Pain Intensity Difference (SPID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).
score on a scaleMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Summed Pain Intensity Difference (SPID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).23.4 (-34.08 to 74.17)10.4 (-26.78 to 65.43)9.5 (-30.68 to 79.98)-1.3 (-22.42 to 47.50)
SecondaryVAS Pain Intensity Difference (PID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).

VAS Pain intensity difference (PID) at each scheduled assessment time point after Time 0. A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced.

Time frame:
48 hours after the first dose
Reported as:
Mean · score on a scale
VAS Pain Intensity Difference (PID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).
score on a scaleMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
VAS Pain Intensity Difference (PID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).52.50 ± 2.7338.95 ± 2.6945.04 ± 3.0537.24 ± 3.90
SecondaryVAS Pain Intensity Score-marking on a 100 mm VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). A High VAS Score Indicates a More Intensive Pain Level Experienced.

VAS Pain intensity score at each scheduled assessment time point VAS pain intensity score-marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). A high VAS score indicates a more intensive pain level experienced.

Time frame:
48 hours after the first dose
Reported as:
Mean · score on a scale
VAS Pain Intensity Score-marking on a 100 mm VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). A High VAS Score Indicates a More Intensive Pain Level Experienced.
score on a scaleMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
VAS Pain Intensity Score-marking on a 100 mm VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). A High VAS Score Indicates a More Intensive Pain Level Experienced.18.43 ± 2.8529.28 ± 2.5927.21 ± 3.2228.22 ± 3.48
SecondarySPID-6, SPID-12, SPID-24-VAS SPID Over 0 to 6 Hours (SPID-6), Over 0 to 12 Hours (SPID-12), and Over 0 to 24 Hours (SPID-24) After Time 0 (=the First Dose)

Time adjusted SPID-6, SPID-12, SPID-24 were derived in a similar manner to the Time-adjusted SPID-48 (i.e. up until the first Pre-Rescue VAS inclusive). Please see the primary outcome measure descriptions. Each of these variables were derived from VAS (Visual Analogue Scale) scores recorded prior to the first dose of rescue medication in the first 6 (to calculate SPID6), 12 (to calculate SPID12) or 24 hours (to calculate SPID24) of the study. VAS pain intensity scores were obtained by marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). The VAS was completed at rest.

Time frame:
6, 12, 24 hours after the first dose
Reported as:
Mean · score on a scale
SPID-6, SPID-12, SPID-24-VAS SPID Over 0 to 6 Hours (SPID-6), Over 0 to 12 Hours (SPID-12), and Over 0 to 24 Hours (SPID-24) After Time 0 (=the First Dose)
score on a scaleMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
SPID 620.10 (-34.08 to 61.14)10.13 (-26.78 to 65.43)9.01 (-30.68 to 61.92)-1.49 (-22.42 to 47.50)
SPID 1220.63 (-34.08 to 71.60)9.42 (-26.78 to 65.43)8.44 (-30.68 to 69.40)-1.66 (-22.42 to 47.50)
SPID 2421.99 (-34.08 to 77.47)9.59 (-26.78 to 65.43)8.64 (-30.68 to 73.19)-1.54 (-22.42 to 47.50)
SecondaryTOTPAR-6, TOTPAR-12, TOTPAR-24, TOTPAR-48

Total Pain Relief (TOTPAR) is a measure of total Area Under the Curve of Pain Relief scores. In the event that a patient required rescue medication, the TOTPAR endpoints were calculated using Pain Relief Assessments recorded prior to the first dose of rescue (i.e. inclusive of the first pre-rescue Pain Relief score). Pain relief scores were obtained by marking on a 5-point categorical rating at scheduled time points. The high score means more pain relief experienced: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Each of these variables were derived from pain relief scores recorded prior to the first dose of rescue medication in the first 6 (0-48), 12 (0-48), 24 (0-48) or 48 (0-48) hours of the study.

Time frame:
6, 12, 24, 48 hours after the first dose
Reported as:
Mean · score on a scale*hour
TOTPAR-6, TOTPAR-12, TOTPAR-24, TOTPAR-48
score on a scale*hourMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
TOTPAR 66.84 (0.0 to 22.6)4.59 (0.0 to 22.5)3.34 (0.0 to 21.2)1.60 (0.0 to 11.0)
TOTPAR 1211.86 (0.0 to 46.6)6.74 (0.0 to 38.9)4.46 (0.0 to 35.2)1.82 (0.0 to 18.0)
TOTPAR 2422.13 (0.0 to 94.6)8.66 (0.0 to 66.5)6.51 (0.0 to 71.2)2.49 (0.0 to 47.1)
TOTPAR 4843.98 (0.0 to 190.5)13.28 (0.0 to 138.5)11.95 (0.0 to 131.2)4.51 (0.0 to 139.2)
SecondaryTime to the Onset of Analgesia-Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Meaningful Pain Relief) Using the Two-stopwatch Method

Two-stopwatch method 1. Start two stopwatches ('Stopwatch A' and 'Stopwatch B') at the same time that the infusion of study drug is initiated. This is Time 0. 2. The participant is given 'Stopwatch A' and instructed to "Stop 'Stopwatch A' when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now." (Perceptible Pain Relief) 3. When the participant stops the 'Stopwatch A', the participant then was asked "Do you consider the pain relief you experienced meaningful?" 4. If the participant answered "No", then the participant was given the "Stopwatch B" and instructed to "Stop 'Stopwatch B' when you feel the pain relief is meaningful to you" (Meaningful Pain Relief) 5. If the subject did not experience "perceptible pain relief, they would retain 'Stopwatch A' for the entire 6 hour evaluation period.

Time frame:
6 hours
Reported as:
Median · minutes
Time to the Onset of Analgesia-Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Meaningful Pain Relief) Using the Two-stopwatch Method
minutesMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Time to the Onset of Analgesia-Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Meaningful Pain Relief) Using the Two-stopwatch Method9.4 (6.5 to 11.8)23.9 (13.5 to 39.2)13.8 (6.5 to 24.4)0 (9.9 to 0)
SecondaryPercentage of Participants With Complete Pain Relief

Pain relief score was assessed on a 5-point categorical scale at each scheduled time point after Time 0: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Assessed at scheduled time points: * 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6 hours after the first dose of the study drug * Immediately before and 2 hours after each subsequent dose (doses 2-8) of the study drug while awake * At the end of 48 hours of double-blind treatment period * Immediately before taking each dose of the rescue medication if additional analgesia is required. * At the time of withdrawal (if applicable)

Time frame:
48 hours after the first dose
Reported as:
Count of participants · Participants
Percentage of Participants With Complete Pain Relief
ParticipantsMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Percentage of Participants With Complete Pain Relief297164
SecondaryPercentage of Participants Who Obtained a Peak Pain Relief -Value of 3 ('A Lot of Relief') or 4 ('Complete Relief') Prior to the First Dose of Rescue

Peak Pain Relief was assessed on Pain Relief scores (on a 5 point categorical rating-please see outcome measure description No. 7) recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). The percentage of participants who achieve the peak pain relief was summarized.

Time frame:
48 hours after the first dose
Reported as:
Count of participants · Participants
Percentage of Participants Who Obtained a Peak Pain Relief -Value of 3 ('A Lot of Relief') or 4 ('Complete Relief') Prior to the First Dose of Rescue
ParticipantsMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Percentage of Participants Who Obtained a Peak Pain Relief -Value of 3 ('A Lot of Relief') or 4 ('Complete Relief') Prior to the First Dose of Rescue221143
SecondaryTime to Peak Pain Relief

Time to peak pain relief-Peak Pain Relief was assessed on Pain Relief scores recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). Time for participants who experienced peak pain relief was summarized. Note: For the reader to interpret this outcome measure, a very short Time to Peak Pain Relief indicates the absence of analgesic effect for a treatment because peak pain relief was determined prior to the first dose of rescue medication (or 48 hours if no rescue medication was used).

Time frame:
48 hrs after the first dose
Reported as:
Mean · hours
Time to Peak Pain Relief
hoursMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Time to Peak Pain Relief4.00 ± 1.172.46 ± 0.861.47 ± 0.550.91 ± 0.60
SecondaryPercentage of Subjects Using Rescue Medication

The percentage of participants who used at lease one dose of rescue medication was summarized in each treatment group

Time frame:
48 hrs after the first dose
Reported as:
Count of participants · Participants
Percentage of Subjects Using Rescue Medication
ParticipantsMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Percentage of Subjects Using Rescue Medication56707048
SecondaryTime to the First Dose of Rescue Medication

Time to first use of rescue medication (duration of analgesia)

Time frame:
48 hrs
Reported as:
Mean · hours
Time to the First Dose of Rescue Medication
hoursMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Time to the First Dose of Rescue Medication12.98 ± 1.875.62 ± 0.833.09 ± 0.352.92 ± 0.53
SecondaryTotal Use of Rescue Medication

Total use of rescue analgesia over 0 to 24 hours and over 0 to 48 hours

Time frame:
24, 48 hrs after the first dose
Reported as:
Mean · mg
Total Use of Rescue Medication
mgMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Total Dose in 48 hrs22.9 ± 2.433.1 ± 2.732.4 ± 2.744.7 ± 3.8
Total Dose in 24 hrs17.2 ± 1.723.7 ± 1.622.1 ± 1.429.6 ± 2.0
SecondaryThe Percentage of Participants Who Evaluated Their Study Drug as " Excellent" on a 5-point Categorical Scale Global Evaluation of Study Drug

At the end of 48 hours study period, participants will be asked to " How do you rate the study medication?" on a 5 point categorical scale: 1. Poor 2. Fair 3. Good 4. Very Good 5. Excellent The high score means the participants believed that a better treatment for pain relief received.

Time frame:
48 hrs after the first dose
Reported as:
Count of participants · Participants
The Percentage of Participants Who Evaluated Their Study Drug as " Excellent" on a 5-point Categorical Scale Global Evaluation of Study Drug
ParticipantsMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
The Percentage of Participants Who Evaluated Their Study Drug as " Excellent" on a 5-point Categorical Scale Global Evaluation of Study Drug24581
SecondaryNumber of Participants With Treatment Emergent Adverse Events (AEs)

Treatment-emergent Adverse events coded to MedDRA v 20.0 Preferred Term and System Organ Class Code were tabulated as the counts and percentages by treatment group.

Time frame:
Day 7
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
ParticipantsMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
Number of Participants With Treatment Emergent Adverse Events (AEs)52455839

Adverse events

Collected over Participants were followed up for adverse events during the 48 hour study period. Any AEs which were not resolved by the end of the 48 hour study period were followed up at 30 days.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maxigesic IV0/75 (0%)0/75 (0%)52/75 (69.3%)
IV Acetaminophen0/75 (0%)0/75 (0%)45/75 (60%)
IV Ibuprofen0/76 (0%)0/76 (0%)58/76 (76.3%)
Placebo IV0/50 (0%)0/50 (0%)39/50 (78%)
Most frequent other events
Showing 10 of 38
Most frequent other events
EventMaxigesic IVIV AcetaminophenIV IbuprofenPlacebo IV
NauseaGastrointestinal disorders22/7525/7526/7616/50
VomitingGastrointestinal disorders16/7511/755/761/50
HeadacheNervous system disorders4/755/755/7610/50
DizzinessNervous system disorders13/757/757/768/50
Infusion site extravasationGeneral disorders2/752/755/767/50
Infusion site painGeneral disorders10/750/757/761/50
ConstipationGastrointestinal disorders4/754/754/764/50
SomnolenceNervous system disorders5/756/756/763/50
Muscle spasmsMusculoskeletal and connective tissue disorders1/751/750/764/50
PruritusSkin and subcutaneous tissue disorders5/753/754/762/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)Maxigesic IVIV AcetaminophenIV IbuprofenPlacebo IVTotal
Mean42.3 ± 11.641.9 ± 12.543.3 ± 12.341.7 ± 12.742.4 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Maxigesic IVIV AcetaminophenIV IbuprofenPlacebo IVTotal
Female62586540225
Male1317111051
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Maxigesic IVIV AcetaminophenIV IbuprofenPlacebo IVTotal
Hispanic or Latino181815758
Not Hispanic or Latino56566041213
Unknown or Not Reported11125
Region of Enrollment
Region of Enrollment(Participants)Maxigesic IVIV AcetaminophenIV IbuprofenPlacebo IVTotal
United States75757650276
Baseline Pain Intensity Level
Baseline Pain Intensity Level(scores on a 100mm long scale)Maxigesic IVIV AcetaminophenIV IbuprofenPlacebo IVTotal
Mean69.3 ± 15.866.2 ± 14.268.9 ± 14.468.1 ± 15.868.1 ± 15.0
08

Study locations

2 sites
  • Chesapeake Reserach Group
    Pasadena, Maryland 21122, United States
  • Optimal Research
    Austin, Texas 78705, United States
09

References and documents

Publications

  • Ferguson MC, Schumann R, Gallagher S, McNicol ED. Single-dose intravenous ibuprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2021 Sep 9;9(9):CD013264. doi: 10.1002/14651858.CD013264.pub2. PubMed 34499349 ↗
  • Daniels SE, Playne R, Stanescu I, Zhang J, Gottlieb IJ, Atkinson HC. Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial. Clin Ther. 2019 Oct;41(10):1982-1995.e8. doi: 10.1016/j.clinthera.2019.07.008. Epub 2019 Aug 22. PubMed 31447129 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — It is not planned to publish individual participant data.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Jun 2017, 8 months.

Results were first posted in Jul 2021, 4 years after primary completion. A results delay was requested in Oct 2018.

Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 8 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2016
First posted
Feb 23, 2016
StartActual
Oct 26, 2016
Primary completionActual
Jun 30, 2017
CompletionActual
Sep 15, 2017
Results delay requested
Oct 16, 2018
Results first posted
Jul 6, 2021
Last update
Jul 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02689063
Lead sponsor
AFT Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Feb 23, 2016
Start date
Oct 26, 2016
Primary completion
Jun 30, 2017
Completion
Sep 15, 2017
Results posted
Jul 6, 2021
Last update
Jul 6, 2021

Study contacts

Stephen E Daniels, DO
principal investigator · Optimal Research LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acetaminophen · Ibuprofen

Start the discussion